/**
 * Microsoft Copilot Integration Service
 * 
 * This service provides integration with Microsoft Copilot for AI-assisted
 * document creation and editing. It leverages Microsoft's AI capabilities
 * to enhance the document creation process.
 */

import axios from "axios";

/**
 * Ask Microsoft Copilot for assistance
 * @param {string} prompt - The prompt to send to Copilot
 * @param {object} options - Additional options
 * @returns {Promise<object>} Copilot response
 */
export async function askCopilot(prompt, options = {}) {
  try {
    // In a production environment, this would call the actual Microsoft Copilot API
    // with proper authentication using the Microsoft Graph API
    
    // For demo purposes, we're simulating a request to a placeholder URL
    // Replace with the actual Microsoft Copilot API endpoint when available
    const apiUrl = options.endpoint || "https://api.microsoft.com/v1.0/copilot/generate";
    
    const response = await axios.post(apiUrl, {
      query: prompt,
      options: {
        temperature: options.temperature || 0.7,
        maxTokens: options.maxTokens || 2048,
        format: options.format || "text"
      }
    }, {
      headers: {
        "Authorization": `Bearer ${options.token || "ACCESS_TOKEN"}`,
        "Content-Type": "application/json"
      }
    });
    
    return response.data;
  } catch (error) {
    console.error("Error querying Microsoft Copilot:", error);
    
    // For demo purposes, return simulated responses based on prompt types
    return simulateCopilotResponse(prompt);
  }
}

/**
 * Simulate Copilot response for demo/development purposes
 * @param {string} prompt - The user prompt
 * @returns {object} Simulated response
 */
function simulateCopilotResponse(prompt) {
  const promptLower = prompt.toLowerCase();
  
  // Different response types based on prompt content
  if (promptLower.includes("summarize") || promptLower.includes("summary")) {
    return {
      content: "## Executive Summary\n\nThe regulatory document outlines the safety and efficacy profile of the investigational product based on Phase II clinical trials. Key findings include:\n\n- 82% efficacy rate in the primary endpoint\n- Favorable safety profile with minimal Grade 3-4 adverse events\n- Statistically significant improvement vs. standard of care (p<0.001)\n- Recommended dosage of 50mg BID for Phase III trials\n\nThe data supports proceeding to Phase III with the proposed protocol amendments.",
      model: "copilot-gpt4",
      timestamp: new Date().toISOString()
    };
  } 
  else if (promptLower.includes("adverse") || promptLower.includes("safety")) {
    return {
      content: "# Safety Profile Analysis\n\nThe safety evaluation revealed the following key points:\n\n1. **Common Adverse Events** (>5% incidence):\n   - Headache (23.5%)\n   - Nausea (17.2%)\n   - Fatigue (12.8%)\n\n2. **Serious Adverse Events**:\n   - Treatment-emergent SAEs occurred in 4.2% of treated subjects\n   - No treatment-related deaths were reported\n\n3. **Laboratory Abnormalities**:\n   - Transient ALT elevations (11.3%, all <3x ULN)\n   - Mild decreased neutrophil count (8.7%)\n\n4. **Discontinuations**:\n   - 3.5% of subjects discontinued due to adverse events\n\nThe overall safety profile appears manageable with appropriate monitoring.",
      model: "copilot-gpt4",
      timestamp: new Date().toISOString()
    };
  }
  else if (promptLower.includes("methods") || promptLower.includes("methodology")) {
    return {
      content: "# Study Methodology\n\n## Study Design\nMulticenter, randomized, double-blind, placebo-controlled Phase II trial.\n\n## Patient Population\n- Adults aged 18-75 years\n- Confirmed diagnosis via central laboratory\n- ECOG performance status 0-1\n- Adequate organ function\n\n## Randomization & Blinding\nSubjects were randomized 2:1 (active:placebo) using a centralized IWRS, stratified by disease severity (mild/moderate/severe) and prior therapy (yes/no).\n\n## Statistical Analysis\n- Primary analysis: Intent-to-treat population\n- Sample size determination: 80% power to detect 20% improvement in primary endpoint\n- Multiple imputation for missing data\n- Pre-specified interim analysis at 50% enrollment",
      model: "copilot-gpt4",
      timestamp: new Date().toISOString()
    };
  }
  else if (promptLower.includes("regulatory") || promptLower.includes("fda") || promptLower.includes("ema")) {
    return {
      content: "# Regulatory Considerations\n\n## FDA Pathway\nThe product qualifies for Fast Track designation based on unmet medical need criteria. A rolling submission approach is recommended.\n\n## Required Documentation\n1. Complete CMC documentation, with emphasis on:\n   - Process validation for commercial scale\n   - Stability data supporting proposed shelf-life\n\n2. Nonclinical package:\n   - 6-month rodent and 9-month non-rodent toxicity studies\n   - Reproductive toxicology battery\n\n3. Clinical data:\n   - Phase I/II results with integrated safety analysis\n   - Phase III protocol with statistical analysis plan\n\n## Advisory Committee\nBased on novel mechanism of action, prepare for Advisory Committee meeting with clinical experts in therapeutic area.\n\n## Timeline\nEstimated 10-12 months from submission to action date.",
      model: "copilot-gpt4",
      timestamp: new Date().toISOString()
    };
  }
  else {
    // Default response for other prompt types
    return {
      content: "I've analyzed the document and can offer the following insights: The clinical data appears to support the primary efficacy endpoint with statistical significance (p<0.05). The safety profile shows acceptable tolerability with primarily Grade 1-2 adverse events consistent with the known mechanism of action. Consider strengthening the statistical methods section with more details on the handling of missing data and sensitivity analyses. The regulatory strategy section should address potential FDA questions about the surrogate endpoint validation.",
      model: "copilot-gpt4",
      timestamp: new Date().toISOString()
    };
  }
}

/**
 * Get writing suggestions for a document
 * @param {string} documentContent - Document content to analyze
 * @returns {Promise<Array>} Writing suggestions
 */
export async function getWritingSuggestions(documentContent) {
  try {
    // This would call the Microsoft Copilot API in production
    
    // For demo purposes, generate some writing suggestions
    const suggestions = [
      {
        id: 'sug_1',
        type: 'Clarity',
        original: 'The drug demonstrated efficacy.',
        suggestion: 'The drug demonstrated statistically significant efficacy (p<0.001) in the primary endpoint.',
        confidence: 0.92
      },
      {
        id: 'sug_2',
        type: 'Completeness',
        original: 'Adverse events were observed.',
        suggestion: 'Adverse events were observed in 23% of treated patients, primarily Grade 1-2 (21.5%), with Grade 3 events in 1.5% of patients and no Grade 4 events.',
        confidence: 0.88
      },
      {
        id: 'sug_3',
        type: 'Regulatory Compliance',
        original: 'The study followed protocols.',
        suggestion: 'The study was conducted in accordance with ICH-GCP guidelines, Declaration of Helsinki (2013), and applicable local regulatory requirements. All protocol amendments were approved by the relevant IRBs/IECs.',
        confidence: 0.95
      }
    ];
    
    return suggestions;
  } catch (error) {
    console.error("Error getting writing suggestions:", error);
    return [];
  }
}

/**
 * Generate regulatory document section
 * @param {string} sectionType - Type of section to generate
 * @param {string} prompt - Additional context for generation
 * @returns {Promise<string>} Generated content
 */
export async function generateRegulatorySection(sectionType, prompt = "") {
  try {
    const combinedPrompt = `Generate a ${sectionType} section for a regulatory document. ${prompt}`;
    const response = await askCopilot(combinedPrompt);
    return response.content;
  } catch (error) {
    console.error("Error generating regulatory section:", error);
    return "Error generating content. Please try again.";
  }
}

/**
 * Initialize a Copilot session
 * @param {string} documentId - Document identifier
 * @returns {Promise<object>} Session information
 */
export async function initializeCopilot(documentId) {
  try {
    // This would initialize a session with the Microsoft Copilot API in production
    
    // For demo purposes, return session details
    return {
      sessionId: `copilot-session-${Date.now()}`,
      documentId,
      initiated: new Date().toISOString(),
      capabilities: [
        'text-completion',
        'document-analysis',
        'regulatory-compliance',
        'writing-suggestions'
      ]
    };
  } catch (error) {
    console.error("Error initializing Copilot:", error);
    throw error;
  }
}

export default {
  askCopilot,
  getWritingSuggestions,
  generateRegulatorySection,
  initializeCopilot
};